Inhibition of smooth muscle cell migration by heme oxygenase I
US6203991A · kind A · utility
24Cited by
1References
28Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 20, 1999 |
| Grant date | Mar 20, 2001 |
| Priority date | — |
| Expiry date | Aug 20, 2019 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K48/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present method provides a method for inhibiting restenosis associated with mechanical injury of a blood vessel. Human heme oxygenase I (HO1) is directly administered at the site of injury. The present inventors have discovered that carbon monoxide generated by HO1 is involved in the molecular pathogenesis of vascular proliferative disorders. By using adenoviral-mediated expression of inducible heme oxygenase 1 in primary vascular smooth muscle cells (vsmc) in vivo, the present inventors demonstrate that in vivo expression of HO1 can be used to treat restenosis.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.